Galcanezumab reduces acute headache medication use in treatment-resistant migraineMay 22, 2022Headache & Migraine
Migraine: Suboptimal first-dose responders may benefit from a second dose of eptinezumabMay 22, 2022Headache & Migraine
Evidence of real-world effectiveness of erenumab against chronic migraineMay 22, 2022Headache & Migraine
Fremanezumab can prevent migraine across a broad real-world patient populationMay 22, 2022Headache & Migraine
Meta-analysis backs the clinically significant effects of transcutaneous nerve stimulation in migraineApril 25, 2022Headache & Migraine
Fremanezumab effective and safe for high-frequency episodic and chronic migraine in real worldApril 25, 2022Headache & Migraine
CGRP mAb vs. standard treatments offer better adherence and persistence in migraineApril 25, 2022Headache & Migraine
Ultrasound-guided stellate ganglion block: An effective treatment strategy for migraineApril 25, 2022Headache & Migraine
Effect of CGRP-receptor mAb therapy resumption after a drug holiday on migraine frequencyApril 25, 2022Headache & Migraine
Chronic migraine: Topiramate performs better when combined with greater occipital nerve blockApril 25, 2022Headache & Migraine
External trigeminal nerve stimulation: A nonpharmacological alternative for the acute treatment of migraine attacksApril 25, 2022Headache & Migraine
Fremanezumab effective in difficult-to-treat migraine with associated neurological dysfunctionApril 25, 2022Headache & Migraine
